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Abstract 
 Periodontitis is a polymicrobial chronic inflammatory disease of tooth-supporting tissues 
with bacterial etiology affecting all age groups, becoming chronic in a subgroup of older 
individuals. Periodontal pathogens Porphyromonas gingivalis, Tannerella forsythia, and 
Treponema denticola are implicated in the development of a number of inflammatory 
pathologies at remote organ sites, including Alzheimer’s disease (AD). The initial inflammatory 
hypothesis proposed that AD hallmark proteins were the main contributors of central nervous 
system (CNS) inflammation. This hypothesis is expanding to include the role of infections, 
lifestyle, and genetic and environmental factors in the pathogenesis of AD. Periodontal disease 
(PD) typifies a condition that encompasses all of the above factors including pathogenic bacteria. 
These bacteria not only are the source of low-grade, chronic infection and inflammation that 
follow daily episodes of bacteremia arising from everyday tasks such as brushing, flossing teeth, 
chewing food, and during dental procedures, but they also disseminate into the brain from 
closely related anatomical pathways. The long-term effect of inflammatory mediators, 
pathogens, and/or their virulence factors, reaching the brain systemically or otherwise would, 
over time, prime the brain’s own microglia in individuals who have inherent susceptibility traits. 
Such susceptibilities contribute to inadequate neutralization of invading agents, upon reaching 
the brain. This has the capacity to create a vicious cycle of sustained local inflammatory milieu 
resulting in the loss of cytoarchitectural integrity and vital neurons with subsequent loss of 
function (deterioration in memory). The possible pathways between PD and AD development are 
considered here, as well as environmental factors that may modulate/exacerbate AD symptoms.  
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Introduction 
 Alzheimer’s disease (AD), a form of dementia, is the most common neurodegenerative 
disease worldwide [1]. The prevalence of AD increases exponentially with age, rising from 3% 
among the 65 to 74 year age group and to almost 50% among those around 85 years and older [2, 
3]. Mental deterioration is slow but progressive, contributing to poor memory, disorientation, 
confusion, and eventually profound dementia. Susceptible individuals can take decades before 
clinically presenting with the disease. This implies that the etiology of AD is heterogeneous and 
that the importance of finding new risk factors for development in the case of late-onset AD 
remains a priority.  
 Although partial efficacy of non-steroidal anti-inflammatory drugs in some AD patients [4, 
5] gave rise to the inflammatory hypothesis that accounts for the intrinsic elements of CNS 
inflammation [6], support also exists for the extrinsic inflammatory mediators. The elderly, for 
example, having suffered multiple episodes of recurrent infections, can present with dementia 
like clinical symptoms in likely late-onset AD cases [7] as well as those subjects with confirmed 
clinical diagnoses of AD [8, 9].  
 The innate immune responses suggest extrinsic inflammatory cytokines are involved in 
exacerbating neurocognition [9] and cytokine-related genes are being implicated in the 
susceptibility to inflammation in late-onset AD [10, 11, 12]. Furthermore, human brain tissue 
specimens from postmortem AD patients demonstrate evidence for neuroinflammation via the 
activated complement system as C1q, C3b, and reactive oxygen species are all involved in the 
amyloid fibril formation [11,13, 14]. These observations are strengthened by genome-wide 
studies supporting the role of innate immune components such as complement receptor 1 (CR1) 
and a fluid-phase regulatory protein clusterin [15, 16]. 
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Pathological Hallmarks of Alzheimer’s Disease  
 In AD, marked neuronal loss is observed in the hippocampus where high densities of the 
classical hallmark lesions are initially observed [17]. An accumulation of intraneuronal 
neurofibrillary tangles (NFTs) and extracellular amyloid-β (Aβ) plaques are the two easily 
demonstrated histological features of AD brains [18]. Synaptic dysfunction is considered as one 
of the earliest structural defects [19]. Specifically, NFTs indicate the severity of disease with Aβ 
plaques depicting disease progression [17]. NFTs in neurons constitute hyperphosphorylated tau 
protein that alters the polymerization and stability of microtubules [20]. The loss of synapses 
between neurons correlates well with cognitive decline [19]. The cumulative knock-on effect of 
these cytoarchitectural changes is compromised protein-protein interactions with other 
cytoskeletal elements eventually leading to further synaptic loss and the demise of the NFT-
bearing neurons [17, 18, 20, 21].  
 Amyloid plaques are largely made up of fibrillary Aβ peptides Aβ40/42 amino-acid residues 
and are the result of α-, β-, and γ-secretase enzymes cleaving the transmembrane amyloid-β 
protein precursor expressed by all CNS cells. The proteolytic fragment consisting of the last 28 
residues of the amyloid-β protein precursor ectodomain prior to the membrane and including the 
first 12 to -14 residues of the transmembrane region generate Aβ40/42 amino-acid residues that 
lead to deposition of extracellular, insoluble fibrillar Aβ. Clearing insoluble Aβ peptides from the 
brain involves phagocytosis by microglial cells [22, 23], an activity that invariably fails with the 
consequences of further accumulation of fibrillary Aβ. 
 Aβ peptides and insulin are known substrates of an insulin-degrading enzyme [24, 25]. Both 
of these proteins are important in the pathogenesis of AD and type II diabetes mellitus, 
respectively. Literature supports the risk-factor relationship between type II diabetes with 
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increased risk of cognitive impairment and dementia via its potential pro-inflammatory toxicity 
from perturbed glucose metabolism [26]. However, it is not clear if Aβ itself promotes insulin 
resistance in AD with the generation of subsequent oxidative stress, reactive oxygen species, and 
related pro-inflammatory cascades [27]. Streptozotocin used for generating experimental diabetic 
rats as a model for investigating late-onset AD in relation to insulin resistance is a toxin derived 
from Streptomyces species of bacteria [28]. It is, therefore, plausible to suggest that an initial 
microbial trigger may be responsible for insulin resistance and the subsequent deposition of Aβ 
in late-onset AD.  
 Aβ plaques can be observed in the brains of cognitively intact individuals, but they are fewer 
and are generally of the diffuse (Aβ40) type, which so far appear to have little pathological 
significance. Of the two forms of amyloid, fibrillary Aβ is regarded as being neurotoxic [29] and 
in vitro studies have shown it to lyse all types of cells by apoptosis [30]. Evidence from 
neuroradiological and neuropathological investigations link this hallmark (Aβ40/42) to the 
initiation of intracerebral inflammatory response in the inherited forms of AD as well as late-
onset AD [14, 31, 32]. 
 The inflammatory element of the disease may be a significant risk factor for late-onset AD, 
specifically as innate immune components such as C1q and C3b are involved with plaque 
maturation [11, 13]. The relevance of detecting C1q and C3b within Aβ40/42 also draws attention 
to the cellular mechanisms involved with regulating inflammation in neurodegeneration and in 
clearing Aβ40/42. The inflammatory components corroborate data from genetic studies proposing 
a relationship between AD and cytokine polymorphisms [12, 33], as well as the complement 
proteins such as clusterin and CR1 in its pathogenesis [15, 16]. With respect to the complement 
activation cascade, CR1 is a membrane-associated complement inhibitory protein that binds C4b 
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and C3b acting at the C3/C5 convertase stage of the alternative and classical complement 
pathway, and clusterin is a fluid-phase protein that interferes with the assembly of the lytic 
membrane attack complex. Decrease in clearance of the lesion by the innate immune system 
contributes to bystander damage that promotes a vicious cycle of chronic intra-cerebral 
inflammatory (high endogenous levels of inflammatory mediators) response [14, 34].  
 
What is Intra-Cerebral Inflammation? 
 In the past the brain was considered as an “immunoprivileged organ,” as elements of the 
immune system [such as neutrophils, naive T cells (adaptive immune system), plasma proteins, 
and extra-cerebral-toxins to prevent inappropriate glial cell activation] cannot cross the blood-
brain barrier (BBB). However, it is now understood that the circumventricular organs are not 
subject to the BBB [35], a region of the brain where infections (both systemic and direct via the 
trigeminal and olfactory nerve pathways (see Figure 1) and inflammatory mediators can access 
the brain [36-38].  
 The brain deals with inappropriate toxins derived locally (Aβ deposits) or from extracerebral 
sources (infectious agents) using its own innate immune system consisting of ependymal cells, 
microglia, astrocytes, and oligodendrocytes [39]. Normally these cells regulate the production 
and uptake of endotoxins and secrete trophic factors that nurture the CNS cells and protect their 
functions [40]. However, following physical damage and/or invasion by foreign agents 
(lipopolysaccharide, LPS), glial cells (specifically microglia) bearing the LPS receptor (CD14) 
and the highly conserved toll-like receptors 2 and 4 (TLR 2 and 4) undergo a number of 
phenotypic (resting to activated state) and functional changes. Key morphological changes 
include thickening and shortening of branching processes attached to a hypertrophic glial cell 
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body [41]. Once activated, microglia upregulate the expression of MHC class II molecules along 
with the secretion of pro-inflammatory cytokines (TNF-α and IL-β), complement proteins, 
quinolinic acid, arachidonic acid and its metabolites, nitric oxide, platelet activating factor, α and 
β chemokines excitatory amino acids, and free radicals [14]. When these innate factors are 
secreted by microglia, a local CNS inflammatory response is mounted.  
 In AD brains, Aβ is recognized as a nidus for intracerebral inflammation placing chronic 
neuroinflammation downstream of this primary hallmark [13, 14]. However, this view is 
changing, especially with late-onset AD cases as the importance of the innate immune molecules 
is being uncovered by genome-wide studies [11]. If nerve cell death and chronic CNS 
inflammation are common precursors of the development of dementia, explaining equivalent 
numbers of Aβ deposits and NFTs in clinical and subclinical AD in the very elderly who bypass 
dementia is important [42-45] and adds further complications to the etiological nature of AD.  
Even Aβ in subclinical AD subjects, which initiates intracerebral inflammation [11, 46, 47], 
appears not to lead to clinical decline in cognition. One possible explanation for the lack of 
cognitive decline could lay in the inflammatory genetic traits of these and the non-impaired 
individuals with vital neuronal cells being rescued from death and so providing a “cognitive 
reserve.” The inflammatory signals that initiate phagocytosis by microglia are driven by Aβ that 
involve the CD14 and TLR 2 and 4 signaling [22, 23, 48, 49], a pathway also used by microglia 
for bacterial LPS recognition [50]. Spontaneous loss-of-function mutation in the TLR 4 gene has 
been demonstrated to have an inhibitory effect on microglial cell activation. For example, 
presence of Aβ in the microglia with mutated gene expression [49] demonstrated reduced 
secretion of inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-α 
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(TNF-α) and nitric oxide. These findings further strengthen the cognitive reserve hypothesis in 
very old subjects in the presence of classical AD hallmark lesions. 
 Using an ex-vivo experimental model to examine the expression of pro-inflammatory 
cytokine profiles in whole blood from the healthy middle-aged offspring of patients affected by 
late-onset AD, van Exel et al. [10] reported higher levels of specific cytokines than were found in 
the siblings from non-AD parents. This finding also demonstrates that inflammation-related risk 
factors are present in currently healthy subjects who may have a genetic ‘susceptibility profile’ a 
phrase, coined by McGeer and McGeer [33] to late-onset AD. Despite the inheritance factors, the 
brain’s response to inflammation is slow as supported by animal models of AD [51]. Currently, 
the greater accumulation of Aβ deposits in late-onset AD is considered to be the result of defects 
in the clearance system [52]. Therefore, the pertinent question would be, “what initially triggers 
Aβ40/42 release in patients with late-onset AD?”  
 Infections are common in elderly individuals and are the main cause of death in a majority of 
neurodegenerative conditions. One hypothesis is that the elderly, per se, are 
immunocompromised and this correlates with their susceptibility to an increased incidence of 
infection [53, 54]. Recurrent bacteremia from common infections in the elderly, due to, for 
example, chronic periodontitis [55, 56], intra-abdominal [57], and urinary tract infections [58], 
will contribute to systemic circulation infections. In addition, chronic periodontitis demonstrates 
a promising link that encompasses environmental influences, susceptibility profiles, infectious 
agents, and a multitude of host’s factors that affect its episodic re-occurrence [59]. Numerous 
studies show that tooth loss due to PD to correlate with cognitive impairment in AD [60-63]. 
Further studies have demonstrated systemically derived immune components such as antibodies 
to the periodontal pathogens circulating in the blood plasma of AD subjects [64]. In addition, AD 
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patients with antibodies to the periodontal pathogens in their blood have displayed inflammatory 
mediators (cytokines) in the systemic circulation [64]. As Holmes et al. [9] suggest, these 
cytokines and those from alternative sources in the peripheral circulation have the potential to 
reach the brain parenchyma, and subsequently prime microglia to mount a local immune 
response with appropriate stimuli, and impair memory.  
 An alternative hypothesis for the role of Aβ in subclinical and/or clinical AD individuals is 
that Aβ is acting as an antimicrobial peptide [65] to counteract infections by functioning as part 
of the early innate immune defense mechanisms that mediate innate and adaptive immune 
responses [66]. Traditionally, antimicrobial peptides act as look-outs for invading micro-
organisms to maintain the balance between commensals. The main target for antimicrobial 
peptides is the pathogen cell membrane, as most antimicrobial peptides are cationic [67]. 
Antimicrobial peptides undergo electrostatic interactions with negatively charged molecules to 
penetrate bacterial cell walls, including anionic lipids and LPS [67]. They then invade the lipid 
bilayer, creating trans-membrane pores through which leakage of ions and metabolites, 
cytoplasmic components, dissipation of electrical potentials, and cell death of microbes takes 
place [68]. This hypothesis suggests the involvement of a pathogenic precursor in the initiation 
of Aβ release before inflammation becomes detectable in the presence of this hallmark. We 
support this hypothesis and propose a suite of susceptibility traits and immunosuppressive 
(stressed or rundown) episodes during life that give way to chronic bacterial infections. These 
bacterial elements in the individuals with susceptibility profiles may trigger release of Aβ to 
neutralize their effect. Over time Aβ will accumulate in the brains of healthy but susceptible 
individuals and initiate neuroinflammation that may cross the threshold from subclinical to late-
onset AD. 
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 The etiological hypothesis suggests that viruses and bacteria and/or their virulence factors 
access the brain and thereby contribute to AD pathogenesis. A review by Holmes and Cotterell 
[69] provides a range of infective agents consistently being linked to AD. These include viruses 
such as Herpes simplex virus type I [70], Chlamydophila pneumoniae [71], Treponema spp.,[72] 
Borrelia burgdorferi [73], and more recently LPS from P. gingivalis [74], one of the key bacteria 
causing PD in humans.  
  
Age-Related Personal Hygiene Changes as Risk for Infections 
 Advancing age is the greatest risk factor for all forms of AD. Some consequences of 
advancing age are a compromised immune system [53, 54] and a neglect of general and oral 
personal hygiene [61, 75, 76], and such conditions are associated with recurrent, chronic 
infections. Recurrent, chronic infections enhance systemic hyperinflammatory profile that may 
lead to confusion and other dementia-like clinical features [7-9] in which the exact 
structural/cellular changes taking place at the time remain unknown. 
 Several studies support deterioration in oral health with increasing age [77-80]. The exact 
reasons are poorly understood, but advancing age is likely to compromise the manual dexterity 
of senior citizens and this may make cleaning their teeth more difficult, or perhaps it is because 
as general health concerns and conditions increase with age, maintenance of oral health becomes 
a lower priority. The elderly are more likely to be on multiple medications, many of which, as a 
side effect, cause xerostomia and this will inevitably be a factor in deteriorating oral health [81]. 
Furthermore, if the elderly suffer from physical impairments, accessing the dentist may become 
more difficult. Elderly people resident in care institutions are, to a certain extent, dependent on 
the level of care within the establishment for the level of oral hygiene and dental health they 
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receive. These factors were supported in a large-scale survey carried out in the US by Griffin et 
al. [79], which found that older age groups were more likely to be edentulous or have untreated 
dental disease and root caries. Those who were either residents in institutions or homebound had 
higher levels of untreated cavities, gingivitis (a marker of poor oral hygiene), and poorer overall 
oral health than the elderly living independently. The study shows that cost, lack of 
transportation, and limited mobility were key barriers to accessing dental care for nursing home 
residents [79]. Other groups of elderly that show higher untreated dental disease and lower levels 
of oral health are those from ethnic minorities and low-income families [79]. 
 
Periodontal Disease 
 PD is a polymicrobial inflammatory disease that has been estimated to affect 10-15% of the 
developed world population and is a major cause of tooth loss. The prevalence of PD increases 
with age, affecting around 50% of people over the age of 55 years [82]. The disease affects tooth 
supporting tissues wherein the interaction of specific bacteria and the host’s immune responses 
play a pivotal role [59]. The host’s response to bacteria and their products is an important factor 
in determining the extent and severity of PD [83]. The acute bacterial challenges stimulate 
junctional transformed pocket epithelium to produce a broad range of inflammatory mediators to 
guard against gingival tissue damage. The inefficient clearance of subgingival pathogens by the 
innate immune system compromises the integrity of periodontal tissues and eventually results in 
the formation of periodontal pockets.  
 Periodontitis, involving specific bacteria coupled with the host’s response, initiates an acute 
phase receptor-mediated cytokine production by epithelial cells and simultaneous neuropeptide 
release, resulting in vasodilation of local vessels. Chemokines mobilize neutrophils from blood 
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vessels for migration to the area of bacterial invasion. Gingival bleeding, swelling, and redness 
together with the presence of neutrophils/macrophages within the inflamed gingivae indicate 
clinical signs of inflammation. The infection is both confined to, and subsequently cleared by, 
neutrophils and macrophages, or expands to include other cells and structures [84]. In the high 
susceptibility profile group of individuals, the acute phase responses fail to clear the infection, 
and chronic inflammatory lesions develop within a matter of weeks. The pathogenic consortium 
consisting of Porphyromonas gingivalis (P. gingivalis), Tannerella forsythia (T. forsythia), and 
Treponema denticola (T. denticola) appear to be the main organisms involved in the 
development of chronic PD [85, 86]. The subgingival sulcus serves as a niche enabling a cyclic 
chronic inflammatory process which in turn facilitates recurrent bacteremia following routine 
oral health regimes [55, 56, 87]. A number of inflammatory pathologies are said to develop in 
this way, including cardiovascular diseases [88, 89], rheumatoid arthritis [90-92], diabetes 
mellitus [93], and others as well as AD [60, 61, 64, 72, 74]. 
 
Anatomical Relationship of Facial Nerves and the Blood Supply to the Brain  
 The position of the oral cavity, serving the need for speech and food consumption, connects 
with the brain via series of nerves. Cranial nerve 1 (CN1) is the special sensory nerve for 
olfaction and contributes not only to our sense of smell but also to that of taste. CN1 has 
complex pathways that trigger visceral responses (salivation and nausea or accelerated peristalsis 
in the intestinal tract and increased gastric secretion) to various odors. Although CN1 is 
recognized and named as the olfactory nerve, the majority of the olfactory tract comprises of 
secondary, rather than primary sensory axons; thus it is really not a “nerve” but rather a bulb and 
tract. There is a physical connection between the oral and nasal cavity, extending onto the 
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superior nasal conchae and nasal septum and contains neurosensory cells and olfactory glands, 
which keep the mucosa moist and in which the dissolution of inhaled scents (aromatic 
molecules) occurs. The peripheral processes of the primary sensory neurons in the epithelium 
perform as sensory receptors and transmit sensation centrally, which congregate into around 20 
bundles, which, in turn, pass through foramina of the cribiform plate of the ethmoid bone. The 
cribiform plate of the ethmoid bone is the porous barrier between the nasal passages and the 
brain itself. Once they have passed through the cribiform plate, the central processes synapse on 
the secondary sensory neurons in the olfactory bulb itself, which houses the nerve cell bodies. 
Behind this area is the olfactory tract and trigone; the nerve cell bodies travel to the three 
olfactory areas, located in the anterior part of the entorhinal cortex area, encompassing the 
hippocampal gyrus and all ultimately lead to the hippocampus [94].  
 Cranial nerve V (CN V) or the trigeminal nerve, arising from the mid-lateral surface for the 
pons, is primarily a general sensory nerve with smaller motor component. There are three 
divisions of the CN V which are ophthalmic (V I), maxillary (V2) and mandibular (V3) where, 
the motor root of CN V travels with the mandibular branch. The ophthalmic division (V I) exits 
the neurocranium through the supraorbital fissure, the maxillary division (V2) through the 
foramen rotundum in the sphenoid bone and the mandibular (V3) branch through the sphenoid’s 
foramen ovale. CN V is a general sensory nerve to the scalp, face, nasal and oral cavities 
(including the teeth and tongue), and brachial motor nerve to the muscles of mastication 
(temporalis, masseter, medial pterygoid, and lateral pterygoid), tensor tympani, tensor (veli) 
palitini, mylohyoid, and the anterior belly of the digastric. When dental or periodontal therapy is 
performed using local anesthesia (e.g., novocaine, xylocaine), the drug is injected into the oral 
mucosa covering the bony foramina where the sensory branches of the CN V exit into the oral 
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cavity. For the maxillary dental arcade, the injection is aimed toward the pterygopalatine 
ganglion; for the mandibular teeth, this is directed toward the mandibular foramen. In the case of 
the pterygopalatine ganglion, this supplies sensation via branches of V2 from the nasal cavity, 
plate, nasopharynx, and maxillary teeth. The lingual and inferior alveolar nerve branches carry 
sensation from the entirety of the lower jaw, mandibular teeth, gums, and anterior two thirds of 
the tongue as shown in Figure 1. As with most nerves, the branches of the trigeminal nerve are 
accompanied by veins and arteries along the peripheries of their pathways [94]. 
 The olfactory and the trigeminal nerve(s) pathways are also exploited by periodontal 
pathogens as a means of bypassing the BBB for direct entry into the CNS [72, 95, 96], an 
observation supported by studies in immunosuppressed animal models using T. denticola [97]. 
The animal model study allows some insight into the virulence of the organism and the host’s 
immune defenses as being important for this occurrence.  
 The systemic route as an alternative mode of bacterial entry into the brain is favored due to 
bacteremia as mentioned earlier, association of periodontal pathogens with atherosclerotic 
lesions and in particular P. gingivalis having the ability to adhere to erythrocytes for innate 
immune evasion [87, 98, 99] as well as gaining advantage for transportation to remote body 
organs [99].  
 The brain is supplied by three paired blood vessels: the right and left internal carotid arteries, 
arising from the common carotid artery at the base of the neck. It has three divisions that enter 
the cranium, anteriorly through the carotid canal of the temporal bone and through foramen 
lacerum in the middle cranial fossa. The vertebral arteries arise from the subclavian arteries, 
bilaterally and both enter the cranium via the foramen magnum. The vertebral and internal 
carotid arteries unite on the base of the brain at the Circle of Willis, via a series of 
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interconnecting smaller arteries. The basilar artery is created when the vertebral arteries join. The 
Circle of Willis itself is composed of the posterior cerebral, posterior communicating, internal 
carotid, anterior cerebral and anterior communicating arteries; all these arteries branch to supply 
the brain itself [94] including the circumventricular organ regions where bacteria and bacterial 
products access the brain.  
 
The Association between Periodontal Disease and Alzheimer’s Disease  
 Longitudinal studies have shown that people with PD who progressed to the development of 
AD had poorer oral health [61, 76, 79, 100-102]. Does poor oral health always mean that the 
pathogens will disseminate to the brain even in AD patients? Both our unpublished data from 
controlled experiments using animal models, and that of Foschi et al. [97], indicate that the 
presence and motility of the low virulence strains of periodontal pathogens may not be sufficient 
for them to access the brain. However, animal models of oral diseases (periodontitis and 
endodontic) may require an adjustment for the optimization of dosage and/or duration of 
infection to allow for bacteria to translocate to the brain. Our unpublished data demonstrates that 
P. gingivalis (FDC381) accessed the brain of ApoEnull mice following an oral infection while P. 
gingivalis (ATCC 33277) failed, even in SCID mice mono and poly infections [97]. It therefore 
appears that the greater virulence of P. gingivalis (FDC 381) due to having acquired fimbriae, 
likely allowed its adherence to erythrocytes for innate immune evasion, a process that has gained 
the bacterium an advantage for dissemination [99], to the brain [Poole et al. unpublished results]. 
When the duration of active infection supersedes the virulence of the bacteria, there remains a 
high possibility that the host harboring the periodontal pathogens will demonstrate these bacteria 
disseminating to the brain. Immunocompromised status seen in AD patients will also enhance the 
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infection process. This begs the question as to what causes some individuals to harbor 
periodontal bacteria rather than other species? Could there be as yet unknown genetic 
factors/inflammatory traits, lifestyle driven environmental stressors? 
 However, it should be noted that patients suffering from AD cognitive impairment are poor 
at managing their personal oral health. In addition, a caregiver or dentist may face a marked 
decrease in co-operation from the AD patient, making management of oral health more 
challenging. With patients having increased cognitive impairment, such as reduced adaptation to 
change, dentists often choose not to carry out the dental treatment that would give optimal oral 
health. For example, patients with AD may well be unable to cope with extensive, potentially 
unpleasant dental procedures, leaving them with fewer teeth, which could have a detrimental 
impact on their eating ability. 
 Nutritional deficiencies are documented in the elderly as well as in the dementia subjects, 
especially with regard to lessened intake of B-vitamins and folic acid in the diet. The marker that 
indicates these deficiencies also correlates with cognitive decline, but as consequence of disease 
rather than a cause [103]. The mechanism of cognitive decline is suggested via synaptic 
dysfunction, which is one of the earliest structural defects associated with decline in memory 
[19]. Diet provides the essential B-vitamins, phospholipids, and other micronutrients, which are 
required for the formation of new synapses [104]. 
 
Epidemiological Evidence for the Association between Chronic Periodontitis and 
Alzheimer’s Disease 
 Clinical/epidemiological studies so far, all agree on loss of teeth leading to poor memory [60-
63]. Further studies have examined possible inflammatory biomarkers in an attempt to link 
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and/or to find new diagnostic makers of AD. Others have, however, used more specific measures 
including IgG levels to P. gingivalis and other specific periodontal pathogens [64, 105]. A study 
by Sparks Stein et al. [105] used cohort methodology analyzing levels of serum antibodies to 
periodontal disease. At the start of the study period, all participants were cognitively intact, but 
higher levels of serum antibodies to periodontal pathogens at baseline led to some individuals 
developing AD [105]. As baseline measures were taken years before diagnosis of AD, the 
elevation in serum antibodies cannot be attributed to secondary effects of AD (for example, poor 
oral hygiene). Although clinical measurements of oral health were not taken in the Sparks Stein 
et al. [105] investigation, periodontal bacterial species are generally accepted as being specific 
enough to PD and assessing serum antibody levels to these pathogens may prove to be a true 
indicator of PD in AD patients.  
 
Possible Confounders 
 Several environmental, epidemiological, and risk factors show similar trends and patterns in 
both PD and AD. Whether or not this is coincidental or arises through shared developmental 
pathways remains unclear. The impact of these associations is the potential for these factors to 
act as confounders, influencing the true relationship between PD and AD. 
 The incidence of both PD and AD increases with age; this has already been mentioned in 
previous sections. Gender related trends exist between AD and periodontal disease. The 
incidence of AD has been shown to be higher in women after 85 years of age. This is thought to 
be due to the protective effect of pre-menopause estrogen [106]. Men, however, have been 
shown to have a greater incidence of PD (up to 50%) than women overall [107]. Interestingly, 
this study also showed that men with PD also had increased incidence of coronary artery disease, 
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suggesting fewer men than women survive to old age. Physical activity has been shown to have a 
positive effect on cognitive function and those aged 70-79 years with high levels of activity show 
lower levels of inflammatory markers such as IL-6 and C-reactive protein [106]. Likewise 
obesity has shown similar trends, in that those who are obese suffer a greater incidence of AD. 
Although physical activity and the incidence of PD have not been investigated directly, many 
studies have shown an indirect relationship, highlighting a greater incidence of PD with obesity 
and diabetes [107, 108]. It has been suggested that obesity may be the second highest risk factor 
for PD after smoking [109]. The underlying mechanism for this association is thought to be 
related to proinflammatory cytokines, including IL-6 and C-reactive protein that are released by 
adipose tissue, along with hormones adipokines or adipocytokines. With the increasing levels of 
evidence supporting inflammatory processes in AD development, it is possible that the 
relationship between AD and obesity may follow similar mechanisms [109]. Poorer general 
health may be associated with PD due to a compromising immune system and therefore, the 
ability of the host to defend against periodontal bacterial infections. 
 It is generally accepted that smoking is the major risk factor in periodontal disease. Smokers 
are 2-7 times more likely to present with PD than non-smokers and this is unrelated to oral 
hygiene. Disease progression is more rapid and response to treatment is poorer [109]. Smoking is 
thought to affect neutrophil function, reducing the host’s ability to eliminate periodontal 
pathogens. Smokers with PD have distinct patterns of pathogenic microbial profile than non-
smokers with PD [110-112]. Smoking is also thought to lead to release of reactive oxidative 
species and oxidative stress mediated tissue damage. Inflammatory cytokine and chemokine 
expression in smokers compared to non-smokers show many differences reflecting the 
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immunosuppressant effect of smoking, which may contribute to an enhanced susceptibility to 
periodontitis [113].  
 The relationship between smoking and AD is less clear; with some studies suggesting 
smoking has a beneficial effect due to nicotine treatment improving cognitive performance in 
age associated memory impairment [114], while others suggesting that smoking increase the risk 
of AD. In the proposed theory, an increased risk of AD is similarly related to the factors causing 
periodontal disease, whereby smoking increases free radical generation leading to high oxidative 
stress, or affects the inflammatory immune system leading to phagocyte activation and further 
oxidative damage. 
 PD would appear to have an increased prevalence in both ethnic minority groups and lower 
socioeconomic status. This has been attributed to a complex combination of social, 
psychological, and structural factors including nutrition, oral hygiene, healthcare utilization, and 
access to care. It is thought that having lack of resources to pay for care, not having a regular 
source of care, or availability of transportation to healthcare centers contribute to these trends 
[115-117].  
 The relationship between race and socioeconomic status and AD appears more complex. 
Meta-analysis assessing the relationship between education level and AD showed that overall 
those with low or no education were more likely to develop AD, but this was not shown in all 
studies. This relationship was stronger in developed, compared to developing countries possibly 
due to life-expectancy being shorter in developing countries. Individuals with less education 
appear to have lower cognitive function compared to those with higher education levels. 
Education-dementia relationship appears to vary according to age, gender, and race/ethnicity and 
the suggestion is that the relationship ties in with a person’s life events beginning prior to and 
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carrying on beyond years of formal education [118]. These epidemiological trends associated 
with both PD and AD demonstrates the importance for excluding the impact of confounders 
when investigating a true relationship between PD and AD. 
 
Genetic Risk Factors for Late-Onset Alzheimer’s Disease and Periodontitis 
 The apolipoprotein E (ApoE) gene is a known genetic risk factor associated with late-onset 
AD, and more recent investigations suggest some further genetic risk factor associations with 
innate immune molecules and inflammatory traits in late-onset AD [10, 15, 16]. In particular, 
cytokine-related genes appear to be involved in the susceptibility to inflammation in late-onset 
AD [10, 12, 33] as well as in PD [119-121].  
 As the immune system plays an important role in PD pathogenesis [59], it is thought that PD 
itself may have genetic associations. Polymorphisms in IL-α, IL-1β, IL-6, and TNF-α genotype 
are reported for periodontitis [119-121] and similarly IL-1α, IL-1β, IL-6, TNF-α, α2-
macroglobulin, and α1-antichymotrypsin are all upregulated in AD [12, 33] suggesting 
commonalities between susceptibility profiles in these two disease conditions. As mentioned 
earlier, offspring of parents with AD have higher inflammatory cytokines in their blood than 
those who are descendants of non-AD parents [10]. Similarly, parents with poor oral health tend 
to have children with poor oral health; however, it is difficult to conclude that the poor oral 
health trait is a result of the genetic makeup of the individual and not simply an environmental 
influence [122].  
 
Stress Environmental and Genetic Factors 
Stress: In health 
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 Acute stressors in the environment, such as facing a dangerous situation, activate 
physiological systems designed to enhance self-preservation [123]. These include the 
sympathetic-adrenal-medullary and the more slowly responding hypothalamus pituitary adrenal 
(HPA) axis. This response prepares the body to cope with threat [124]. The two response 
systems work by increasing certain hormones, such as adrenaline and cortisol. These, in turn, act 
on the biological functioning of the individual, such as increased heart rate, inhibition of the 
digestive system, or increased glucose supply to the muscles. Although the physiological 
changes enhance our ability to mount a physical response to threat, the associated neurochemical 
changes can lead to cognitive failures, which may present as dementia-like even within a 
cognitively normal population. For example, elevations in cortisol as a result of activation of the 
HPA axis can lead to impairments in attention [125], working memory and inhibitory control 
[126], and declarative memory [127]. Cognitive impairments due to acute stressors are 
reversible. Further acute stress responses may actually have some benefits for health with 
enhancements in immune function being reported [128]. However, when short-term beneficial 
adaptations designed to maintain homeostasis during acutely stressful events become excessive 
or prolonged, problems can occur [129].  
 
Stress: Periodontal disease 
 Psychological stress may affect periodontal disease. Such stressors can lead to a change in 
health behaviors, which in turn may lead to associated increased risk of PD. For example, poorer 
oral hygiene coupled with increased smoking [130] and alcohol intake [131]; visiting the dentist 
less regularly, and eating less healthily with higher fat and sugar diets [132] encourage bacterial 
growth and worsen periodontal status.  
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 Stress impairs the balance between pro- and anti-inflammatory responses. Alterations in 
inflammatory polymorphic gene function, in particular of IL-1 and IL-6 (119-121), will affect 
polymorphonuclear leukocyte chemotaxis. The net effect will be reduced lymphocyte 
proliferation and this may increase the vulnerability of periodontal tissue to microorganisms 
leading to further tissue destruction [133]. Inhibition of T cell responses by glucocorticoids 
appears to explain, in part, susceptibility to PD and pro-inflammatory cytokines are potent 
activators of the HPA axis [134, 135]. Patients with PD who are stressed show increased IL-6 
and IL-1β levels in gingival crevicular fluid [133]. Results of several studies were reviewed and 
demonstrated a correlation between psychological stress and salivary and blood stress markers 
relating to inflammatory response and progression of PD [134]. However, a cause and effect 
relationship has not, so far been found, therefore stress is considered a risk factor for PD rather 
than a cause. 
 
Stress: Alzheimer’s disease 
 High levels of environmental stressors could lead to impairments in cognitive processes, 
which are important for maintaining oral hygiene. For example, acute and chronic activation of 
the HPA axis can lead to elevated basal cortisol levels. High levels of circulating cortisol causes 
hippocampal damage and so impair hippocampus-dependent memory processes [125]. In a 
cognitively intact elderly population, higher cortisol levels were indicative of impairments of 
declarative memory and executive functioning [135], both of which are needed to maintain good 
oral hygiene.  
 The hippocampus is the area of pathology in AD and is vulnerable to effects of stress and 
trauma [136]. Chronic stress can impair immune responses and so compromise the body’s ability 
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to resist disease [137]. The brain attempts to compensate cellular stress, by regulatory 
mechanisms, involving upregulation of heat shock proteins [138]. Loss of heat shock proteins, in 
vitro, was shown to contribute to accumulation of hyperphosphorylated tau, a component of 
NFTs, and a hallmark of AD pathology [139]. In addition, stress activated protein kinases, for 
example, mitogen-activated protein kinase 38 and the c-jun N-terminal kinases are activated in 
AD [140, 141]. These two stress pathways can also be activated by oxidative stress [142, 143], a 
common denominator of environmental, pathological, and habitual factors.  
 
Critical Remarks about the Present State of the Research to Relationship between 
Alzheimer’s Disease and Chronic Periodontitis 
 Clinical observational studies thus far all correlate with loss of teeth leading to poor memory. 
However, direct evidence is lacking to support a causal association between periodontal bacteria 
and progression of AD. The clinical studies have been performed on elderly cohorts where 
overlapping features of the aging process, such as deposition of Aβ in the brain is likely to have 
already begun. When assessing periodontal status clinically, levels of caries may not have been 
accounted for. Oral hygiene studies were based on retrospective questionnaire surveys, which 
may introduce selection bias depending on the response rate. People who are motivated to 
complete questionnaires may be more likely to visit the dentist than those who do not. Genetic 
factors have not given importance in some of the studies. Both the Riviere et al. [72] and the 
Poole et al. [74] studies lacked information concerning the periodontal status of the cases 
analyzed.  
 
Future Research 
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 How PD contributes to impaired memory remains intriguing and future studies should be 
directed towards addressing these mechanisms. There is paucity of information relating to the 
exact risk factor(s) for the development of deteriorating memory from missing teeth in the 
prodromal phase of AD. Are these factors downstream of co-morbidities such as diabetes 
affecting periodontal status of the individual? Or common susceptibility profiles play a key role 
in loss or gain of function in future generations of AD parents. Further evidence to support an 
association between PD and AD, research would need to demonstrate that the inflammatory and 
immunological responses that the bacteria and their virulence factors induce may subsequently 
lead to the onset of AD. Perhaps associations between parents with AD and their children at a 
much younger age should be monitored for oral health as that should eliminate any overlapping 
confounders that may be masking the true links in these two conditions.  
 This review clearly indicates significant gaps in our current understanding of the causal 
association of pathogens (spirochetes, bacteria, viruses) in a slowly progressive and debilitating 
disease such as AD. Although various types of neurotropic spirochetes including oral 
(Treponema spp) and non-oral spirochetes (B. burgdorferi) have been detected directly in 
association with the pathological hallmarks of AD [73] but, a causal relationship has not been 
tested in animal models. To the best of our knowledge, there is no single in vivo animal model 
study that has examined the role of periodontal bacteria during chronic infection (9-12 months of 
exposure times) to study the sequence of neuropathological events associated with the 
development of AD pathology. Even though infectious agents have been implicated in relation to 
AD hallmark pathology for over a century ago, several clinical and molecular studies strongly 
support an association between PD and AD. However, to date, there is a paucity of reports 
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supporting a causative relationship between periodontal pathogens and AD cases and in vivo 
transgenic mice. 
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Legends 
 
 
Figure 1. Nerve pathways from the oral and nasal cavity to the brain, showing the 2nd and 3rd 
branches of the Trigeminal (CN V) and the Olfactory nerve (CN I). The middle meningeal artery 
enters the brain at the foramen spinosum in the lateral portion of the greater wing of the 
sphenoid, and then follows the cranial base and lateral potions of the vault, supplying the dura 
and bones of the calvarium. 
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